

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet 1

of 2

**Complete if Known**

Application Number	10/634.114
--------------------	------------

Filing Date	08/04/2003
-------------	------------

First Named Inventor	GLICK, et al
----------------------	--------------

Art Unit	1618
----------	------

Examiner Name	Kim, Vickie Y
---------------	---------------

Attorney Docket Number	UM-08192
------------------------	----------

[illegible][illegible]

**Examiner  
Signature**

Date	
Considered	

5	10	15
---	----	----

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/634,114
Filing Date	08/04/2003
First Named Inventor	Glick, et al
Art Unit	1618
Examiner Name	Kim, Vickie Y
Attorney Docket Number	UM-08192

Sheet 2

of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
V	3	Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770 ✓	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861 ✓	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023 ✓	
	6	Kamal, A. Synlett, 14,(2004), 2533-35 ✓	
	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912 ✓	
	8	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484 ✓	
	9	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259 ✓	

Examiner Signature		Date Considered	5/10/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/634,114
Filing Date	8/4/2003
First Named Inventor	Gary D. Glick
Art Unit	1614
Examiner Name	Kim, Vickie Y
Attorney Docket Number	UM-08192

Sheet 1

of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
V	1	Atwal, K.S. et al., "Small Molecule Mitochondrial F1F0 ATPase Hydrolase Inhibitors as Cardioprotective Agents" J. Med. Chem, 47, pp. 1081-1084 (2004)	
V	2	Atwal, K.S. et al., "N-[1-Aryl-2-(1-imidazo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase" Bioorganic & Medicinal Chem. Ltr	No pub pate
V	3	Hamann, L.G. et al., "Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase" Bioorganic & Medicinal Chemistry Ltrs. 14 pp. 1031-1034 (2004)	


Examiner  
SignatureDate  
Considered

5/10/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/634,114

Filing Date 08/03/2004

First Named Inventor Gary D. Glick et al.

Art Unit Not Assigned

Examiner Name Not Assigned

Attorney Docket Number UM-08192

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56	
	2	Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183	
	3	Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132	
	4	Herranz, Medicinal Research Reviews 23 (2003) 559-603	
	5	Ramdas et al., Archives of Biochemistry and Biophysics 368 (1999) 394-400	
	6	Ursini et al., J. Med. Chem. 43 (2000) 3596-3613	

Examiner Signature

Date Considered

5/10/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192		Serial No.: 10/634,114	
				Applicant: Gary D. Glick <i>et al.</i>			
				Filing Date: 08/04/03		Group Art Unit:	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
[Handwritten marks]	1	4,946,778	08/07/90	Ladner <i>et al.</i>	435	69.6	1/19/89
	2	4,076,823	02/28/78	Wade <i>et al.</i>	424	269	08/18/77
	3	4,110,337	08/29/78	Szarvasi	260	308	03/08/74
	4	4,495,101	01/22/85	Klaubert <i>et al.</i>	260	239.3	04/28/83
	5	4,751,223	06/14/88	Glamkowski <i>et al.</i>	514	219	10/14/86
	6	5,776,946	06/07/98	McGeer <i>et al.</i>	514	307	08/28/95
	7	5,324,726	06/28/94	Bock <i>et al.</i>	514	221	10/29/92
	8	5,597,915	01/28/97	Chambers <i>et al.</i>	540	509	09/15/94
	9	5,041,438	08/20/91	Hsu	514	221	10/30/89
	10	5,861,380	01/19/99	Gyorkos <i>et al.</i>	514	19	12/06/96
	11	6,004,942	12/21/99	Firestein <i>et al.</i>	514	44	12/21/99
	12	6,080,588	06/27/00	Glick	436	508	06/27/00
	13	3,415,814	12/10/68	Calabateas <i>et al.</i>	260	239.3	9/28/66
	14	3,384,635	5/21/68	Calabateas <i>et al.</i>	160	239	6/18/65
	15	3,261,828	7/19/66	Uskokovic <i>et al.</i>	160	239.4	10/14/62
	16	5,288,514	2/22/94	Ellman	427	2	9/14/92
	17	20010016583	08/23/01	Glick <i>et al.</i>	514	220	1/22/01

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
[Handwritten marks]	18	WO 00/19200	06/04/2000	PCT				
	19	0 349 949 A2	10/01/1990	EPO				
	20	WO 90/05305	17/5/90	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)	
[Handwritten marks]	21 Köhler and Milstein, Nature, 256:495-497 [1975]
	22 Kozbor <i>et al.</i> , Immunol. Today, 4:72 [1983]
	23 Huse <i>et al.</i> , Science, 246:1275-1281 [1989]
	24 Adachi, M., <i>et al.</i> , "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," PNAS. USA- 90:1756-1760 (1993)
	25 Adelman, N.E., <i>et al.</i> , "Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; J. Exp. Med.- 158:1350-1355 (1983)
	26 Baader, S.L., <i>et al.</i> , "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroendodermal (SK-N-LO) Cells," Anticancer Research-14:221-228 (1994)
	27 Beale, P.J., <i>et al.</i> , "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," British Journal of Cancer- 82 (2) :436-440 (2000)
	28 Cole <i>et al.</i> , in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985]


Examiner: [Signature]	Date Considered: 5/10/06
-----------------------	--------------------------

<b>EXAMINER:</b>	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
------------------	---

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
				Filing Date: 08/04/03	- Group Art Unit:
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
29	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," <i>J. Org. Chem.</i> -62:1240-1256 (1997)				
30	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," <i>J. Am. Chem. Soc.</i> -114:10997-10998 (1992)				
31	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," <i>PNAS USA</i> -91:4708-4712 (1994)				
32	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," <i>Oncogene</i> -8:3005-3011 (1993)				
33	Cohen, P.L., et al., "Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," <i>Annu. Rev. Immunol.</i> - 9:243-269 (1991)				
34	Crabtree, R.H., "A New Type of Hydrogen Bond," <i>Science</i> 282:2000-2001 1998				
35	Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," <i>Anticancer Research</i> -14:2291-2294 1994				
36	Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [ <sup>3</sup> H]11195: Anatomical and Subcellular Distribution," <i>Brain Research Bulletin</i> , 18:49-61 1987				
37	Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," <i>American Journal of Kidney Diseases</i> - 21(3):239-250 1993				
38	Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," <i>Laboratory Investigation</i> - 61(4):447-456 (1989)				
39	Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," <i>The Journal of Infectious Diseases</i> -166:1223-1227 1992				
40	Garcia-Calvo, M., et al., "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," <i>The Journal of Biological Chemistry</i> - 273(49):32608-32613 1998				
41	Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," <i>Leukemia</i> - 7(5):659-670 (1993)				
42	Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- $\alpha$ in Autoimmune NZB/NZW F1 Mice," <i>Clinical Immunology and Immunopathology</i> - 52:421-434 1989				
43	Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," <i>Arthritis and Rheumatism</i> -18(2):145-152 1975				
44	Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MR1 Mice," <i>J. Exp. Med.</i> -155:1690-1701 1982				
45	Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," <i>Laboratory Investigation</i> - 21(3):199-206 (1969)				
46	Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> - 66:233-243 1991				
47	Koopman, W.J., et al., "The MRL-lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," <i>Scand. J. Rheumatol. - Suppl</i> 75:284-289 1988				
48	Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," <i>Blood</i> - 80(4):879-886 1992				
49	Liu, J.R., et al., "Bcl-2 is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis," <i>Gynecologic Oncology</i> - 70:398-403 (1998)				
50	Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," <i>Immunity</i> -10:629-639 (1999)				
51	Luria, et al., "General Virology - 3rd edition, . 436-446 1978 - Eds. John Wiley & Sons, New York				
52	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>Journal of Medicinal Chemistry</i> - 37(10):1385-1401 1994				
Examiner:		Date Considered: 5/10/06			
EXAMINE: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
				Filing Date: 08/04/03	Group Art Unit:
* (37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
53	Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/lpr Mice by Administration of an Immunoglobulin-Binding peptide," <i>Nature Biotechnology</i> -18:735-739 2000				
54	McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," <i>Nature</i> - 349:254-256 1991				
55	Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," <i>J. Hum. Genet.</i> - 43:2-8 1998				
56	Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing <i>lpr</i> Gene," <i>Clin. Ex p. Immunol.</i> - 63:87-94 1986				
57	Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," <i>Int Arch. Allergy Appl. Immunol.</i> - 88:394-401 (1989)				
58	Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," <i>Seminars in Oncology</i> 26(1)(Supp.2 :84-89 (1999)				
59	Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," <i>Int J. Cancer</i> - 77:913-918 1998				
60	Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," <i>Br. J. Cancer</i> - 74(3) :380-386 1996				
61	Russell, J.H., et al., "Mature T Cells of Autoimmune <i>lpr/lpr</i> Mice have a Defect in Antigen-Stimulated Suicide," <i>Proc. Nat. Acad. Sci. USA</i> - 90:4409-4413 1993				
62	Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," <i>Clinical Immunology and Immunopathology</i> - 87(1):1-7 1998				
63	Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," <i>Proc. Natl. Acad. Sci. USA</i> -90:4708-4712 1993				
64	Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [ <sup>3</sup> H]Ro5-4864 in Rat Brain and Kidney," <i>The Journal of Pharmacology and Experimental Therapeutics</i> - 225(1):61-69 1983				
65	Schwab, M., et al., "Amplified DNA with Limited Homology to <i>myc</i> Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," <i>Nature</i> -305:245-248 1983				
66	Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/imp-lpr/lpr and MRL/Mp-++ Mice," <i>The Journal of Immunology</i> - 1322 :633-639 1984				
67	Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," <i>Cell</i> 67:879-886 1991				
68	Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," <i>Int J. Peptide Protein Res.</i> - 20:451-454 1982				
69	Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," <i>J. Am. Chem. Soc.</i> -118:10650-10651 1996				
70	Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," <i>JNCI</i> -73(1):51-57 1984				
71	Swanson, P.C., et al., "High Resolution Ephope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," <i>J. Immunology</i> - 152(5):2601-2612 1994				
72	Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," <i>J. Clin. Invest.</i> - 97(7):1748-1760 1996				
73	Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," <i>Cell</i> 76:969-976 1994				
74	Theofopoulos, AN, et al., "Murine Models of Systemic Lupus Erythematosus," <i>Advances in Immunology</i> - 37:269-390 1985				
75	Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," <i>Science</i> 267:1456-1462 1995				
76	Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," <i>Nature</i> - 356:314-317 1992				
77	White, E., "Life, Death, and the Pursuit of Apoptosis," <i>Genes &amp; Development</i> - 10:1-15 1996				
Examiner:		Date Considered: 8/10/06			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-08192	Serial No.: 10/634,114
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Gary D. Glick <i>et al.</i>	
				Filing Date: 08/04/03	Group Art Unit:
* (37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
78	Wu, G.Y., et al., "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry 262(10):4429-4432 1987				
79	Wyllie, A.H., "The Genetic Regulation of Apoptosis," Current Opinion in Genetics & Development - 5:97-104 (1995)				
80	Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," J. Ex p. Med. - 183:1533-1544 1996				
81	Zoratti, M., et al., "The Mitochondrial Permeability Transition," Biochimica et Biophysica Acta - 1241:139-176 (1995)				
82	Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders - 6(1):12-20 (1991)				
83	Malgrange, B., et al., "β-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," NeuroReport - 7(18):3041-3045 (1996)				
84	Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia," Society for Neuroscience Abstracts - 24(1-2):979 (1998)				
85	Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro - 3(5):1061-1065 (1994)				
86	Tanimoto, Y., et al., "Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential," Jpn. J. Pharmacol. - 79:177-183 (1999)				
87	Taupin, V., et al., "Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Intedeukin-1 and Tumor Necrosis Factor by Human Monocytes," Lymphokine and Cytokine Research - 10(1):7-13 (1991)				
88	Lowman <i>et al.</i> , J. Biol.Chem - 266:10982 (1991)				
89	Fuh <i>et al.</i> , Science, 256:1677 (1992)				
90	Colosi <i>et al.</i> , J. Biol. Chem., 268:12617 (1993)				
91	A. Monks <i>et al.</i> , J. Natl. Cancer Inst., 83:757-766 (1991)				
92	K.D. Paull <i>et al.</i> , J. Natl. Cancer Inst., 81:1088-1092 (1989) (Abstract only)				
93	E.D. Kerver <i>et al.</i> , Histochem. J., 29:229-237 (1997) (Abstract only)				
94	P.C. Swanson <i>et al.</i> , Biochemistry, 35:1624-1633 (1996) (Abstract only)				
Examiner: 		Date Considered: 9/10/06			
EXAMINE9: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					